Glenmark Pharmaceuticals to Launch Generic Drug for Metabolic Acidosis Treatment in the US Market

Glenmark Pharmaceuticals is set to launch a generic medication for treating metabolic acidosis in the US market. The company expects to commence distribution of the product, which is therapeutically equivalent to Abbott Laboratories' product, this month. The medication achieved annual sales of around $63.8 million for the 12-month period ending August 2025. Glenmark Pharmaceuticals' shares ended 2.72% down at Rs 1,846.45 apiece on the BSE.